Vanda Pharmaceuticals Inc (VNDA) Stock Could Soon Reward Patient Investors

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) is 2.61% higher on its value in year-to-date trading and has touched a low of $3.30 and a high of $7.38 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VNDA stock was last observed hovering at around $4.16 in the last trading session, with the day’s gains setting it 0.17%.

Currently trading at $4.33, the stock is 15.61% and 11.15% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.44 million and changing 4.09% at the moment leaves the stock -13.84% off its SMA200. VNDA registered -39.94% loss for a year compared to 6-month loss of -28.31%. The firm has a 50-day simple moving average (SMA 50) of -$0.67 and a 200-day simple moving average (SMA200) of $11.86.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 10.46% gain in the last 1 month and extending the period to 3 months gives it a 28.11%, and is 24.78% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.72% over the week and 5.54% over the month.

Current P/E ratio is 99.08. Profit margin for the company is 1.30%. Distance from 52-week low is 31.41% and -41.34% from its 52-week high. The company has generated returns on investments over the last 12 months (0.45%).

Vanda Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at $0.05 with sales reaching $48.5M over the same period.The EPS is expected to shrink by -75.00% this year, but quarterly earnings will post -2.40% year-over-year.

Vanda Pharmaceuticals Inc (VNDA) Top Institutional Holders

239 institutions hold shares in Vanda Pharmaceuticals Inc (VNDA), with institutional investors hold 96.40% of the company’s shares. The shares outstanding are 57.53M, and float is at 55.58M with Short Float at 4.13%. Institutions hold 92.51% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 10.81 million shares valued at $71.24 million. The investor’s holdings represent 18.80% of the VNDA Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 4.24 million shares valued at $27.92 million to account for 7.37% of the shares outstanding. The other top investors are State Street Corporation which holds 4.08 million shares representing 7.10% and valued at over $26.89 million, while Renaissance Technologies, LLC holds 5.41% of the shares totaling 3.11 million with a market value of $20.51 million.

Vanda Pharmaceuticals Inc (VNDA) Insider Activity

A total of 1 insider transactions have happened at Vanda Pharmaceuticals Inc (VNDA) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by Wijkstrom Joakim,the company’sSVP, Chief Marketing Officer. SEC filings show that Wijkstrom Joakim sold 3,724 shares of the company’s common stock on Aug 21 at a price of $5.84 per share for a total of $21748.0. Following the sale, the insider now owns 0.11 million shares.

Vanda Pharmaceuticals Inc disclosed in a document filed with the SEC on Aug 10 that Mitchell Stephen Ray (Director) sold a total of 6,500 shares of the company’s common stock. The trade occurred on Aug 10 and was made at $6.05 per share for $39349.0. Following the transaction, the insider now directly holds 29328.0 shares of the VNDA stock.

Still, SEC filings show that on Jul 28, Moran Kevin Patrick (SVP, CFO & Treasurer) disposed off 2,212 shares at an average price of $6.30 for $13945.0. The insider now directly holds 120,714 shares of Vanda Pharmaceuticals Inc (VNDA).

Vanda Pharmaceuticals Inc (VNDA): Who are the competitors?

The company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 110.41% up over the past 12 months. Johnson & Johnson (JNJ) that is -3.01% lower over the same period.